Compugen Ltd. (NASDAQ: CGEN) stock jumped 2.96% on Thursday to $0.96 against a previous-day closing price of $0.93. With 0.84 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.29 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.0000 whereas the lowest price it dropped to was $0.9200. The 52-week range on CGEN shows that it touched its highest point at $2.36 and its lowest point at $0.51 during that stretch. It currently has a 1-year price target of $5.75. Beta for the stock currently stands at 2.65.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CGEN was up-trending over the past week, with a rise of 25.99%, but this was up by 62.29% over a month. Three-month performance surged to 28.45% while six-month performance rose 4.00%. The stock lost -44.65% in the past year, while it has gained 33.79% so far this year. A look at the trailing 12-month EPS for CGEN yields -0.39 with Next year EPS estimates of -0.58. For the next quarter, that number is -0.12. This implies an EPS growth rate of 4.20% for this year and -45.00% for next year.
Float and Shares Shorts:
At present, 86.62 million CGEN shares are outstanding with a float of 81.78 million shares on hand for trading. On Apr 27, 2023, short shares totaled 1.77 million, which was 2.04% higher than short shares on Mar 30, 2023. In addition to Dr. Anat Cohen-Dayag Ph.D. as the firm’s CEO, Pres & Director, Dr. Zurit Levine Ph.D. serves as its Sr. VP of Technology Innovation.
Through their ownership of 17.17% of CGEN’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 2.24% of CGEN, in contrast to 11.07% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in CGEN with 2.31% of the stake, Taylor Frigon Capital Management holds 2,004,594 shares worth 2,004,594. A second-largest stockholder of CGEN, Rock Springs Capital Management L, holds 1,289,990 shares, controlling over 1.49% of the firm’s shares. Renaissance Technologies LLC is the third largest shareholder in CGEN, holding 938,100 shares or 1.08% stake. With a 6.34% stake in CGEN, the Nikko AM Global Umbrella Fund – A is the largest stakeholder. A total of 5,495,822 shares are owned by the mutual fund manager. The Delaware Healthcare Fund, which owns about 0.99% of CGEN stock, is the second-largest Mutual Fund holder. It holds 852,941 shares valued at 0.5 million. Nikko Asset Global All-Biogenome holds 0.93% of the stake in CGEN, owning 801,070 shares worth 0.47 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, CGEN reported revenue of $0.00 and operating income of -$9.64M. The EBITDA in the recently reported quarter was -$9.64M and diluted EPS was -$0.11.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CGEN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CGEN analysts setting a high price target of $13.00 and a low target of $0.50, the average target price over the next 12 months is $5.75. Based on these targets, CGEN could surge 1254.17% to reach the target high and fall by -47.92% to reach the target low. Reaching the average price target will result in a growth of 498.96% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.